Destiny Pharma plc

("Destiny Pharma" or "the Company")

 Exercise of Options and Total Voting Rights

Brighton, United Kingdom - 21 December 2021 - Destiny Pharma (AIM: DEST) a clinical stage biotechnology company focused on the development of novel medicines to prevent life threatening infections, announces that it has issued 10,000 new ordinary shares of 1 pence each in the capital of the Company (the "New Ordinary Shares") following an exercise of share options by an employee.

Application will be made to the London Stock Exchange for the New Ordinary Shares to be admitted to trading on AIM, with dealings expected to commence on 29 December 2021 ("Admission").

Following Admission, the Company will have a total of 59,871,921 Ordinary Shares in issue. Shareholders may use this figure of 59,871,921 Ordinary Shares as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the share capital of the Company under the FCA's Disclosure Guidance and Transparency Rules.

For further information, please contact: 

Destiny Pharma plc 

Neil Clark, CEO 

Shaun Claydon, CFO 

+44 (0)1273 704 440 

[email protected] 

Optimum Strategic Communications 

Mary Clark / Hollie Vile / Manel Mateus

+44 (0) 208 078 4357

[email protected] 

finnCap Ltd (Nominated Adviser and Joint Broker)

Geoff Nash / Kate Bannatyne, Corporate Finance

Alice Lane, Corporate Broking

+44 (0)20 7220 0500

WG Partners (Joint Broker)

Nigel Barnes / Claes Spång

+44 (0)20 3705 9321

MC Services AG

Anne Hennecke / Andreas Burckhardt

+49-211-529252-0

About Destiny Pharma

Destiny Pharma is a clinical stage, innovative biotechnology company focused on the development of novel medicines that can prevent life-threatening infections. Its pipeline has novel microbiome-based biotherapeutics and XF drug clinical assets including NTCD-M3, a Phase 3 ready treatment for the prevention of C. difficile infection (CDI) recurrence which is the leading cause of hospital acquired infection in the US and also XF-73 nasal gel, which has recently completed a positive Phase 2b clinical trial targeting the prevention of post-surgical staphylococcal hospital infections including MRSA. It is also co-developing SporCov, a novel, biotherapeutic product for the prevention of COVID-19 and other viral respiratory infections and has earlier grant funded XF research projects. 

For further information on the company, please visit  https://www.destinypharma.com